We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Indirect Inhibition of Overexpressed Androgen Receptor Activity Halts Growth of Castration-Resistant Prostate Cancer

By LabMedica International staff writers
Posted on 13 Apr 2016
Print article
Image: Space-filling model showing the crystallographic structure of the ligand binding domain of the ROR-gamma (receptor–related orphan receptor gamma) protein (Photo courtesy of Wikimedia Commons).
Image: Space-filling model showing the crystallographic structure of the ligand binding domain of the ROR-gamma (receptor–related orphan receptor gamma) protein (Photo courtesy of Wikimedia Commons).
Cancer researchers have shown that by suppressing the nuclear receptor protein ROR-gamma with small-molecule compounds they could reduce androgen receptor levels in castration-resistant prostate cancer and stop tumor growth.

The androgen receptor (AR) is overexpressed and hyperactivated in human castration-resistant prostate cancer (CRPC). However, the factors that cause AR overexpression have not been thoroughly studied.

Investigators at the University of California, Davis (USA) worked with prostate cancer cell cultures and mouse xenograft models. They reported in the March 28, 2016, online edition of the journal Nature Medicine that retinoic acid receptor–related orphan receptor gamma (ROR-gamma) was overexpressed and amplified in metastatic CRPC tumors, and that ROR-gamma drove AR expression in the tumors. ROR-gamma recruited the proteins nuclear receptor coactivators 1 and 3 (NCOA1 and NCOA3) to an AR–ROR response element (RORE) to stimulate AR gene transcription.

The investigators showed that drugs that blocked ROR-gamma suppressed the expression of both AR and its variant AR-V7 in prostate cancer cell lines and tumors. Drugs that blocked ROR-gamma suppressed tumor growth in multiple AR-expressing xenograft prostate cancer models. The drugs were not effective in AR-negative models. In addition, ROR-gamma blockers effectively sensitized CRPC tumors to the drug enzalutamide, without overt toxicity, in mice.

"This is a new target and a totally new way of hitting prostate cancer," said senior author Dr. Hongwu Chen, professor of biochemistry and molecular medicine at the University of California, Davis. "This strategy targets the root cause of the problem - the overexpression of the AR gene and its protein."

"ROR-gamma has been extensively studied as a target for rheumatoid arthritis, inflammatory bowel disease, psoriasis, and other autoimmune conditions," said Dr. Chen. "Some of the drugs are orally available and have been found to be safe in early clinical trials. They could be a great help for patients with advanced prostate cancer."

Related Links:

University of California, Davis


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.